Wells Fargo & Company Kazia Therapeutics LTD Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Kazia Therapeutics LTD stock. As of the latest transaction made, Wells Fargo & Company holds 500 shares of KZIA stock, worth $2,895. This represents 0.0% of its overall portfolio holdings.
Number of Shares
500
Previous 500
-0.0%
Holding current value
$2,895
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding KZIA
# of Institutions
21Shares Held
2.13MCall Options Held
93.2KPut Options Held
0-
Mai Capital Management1.36MShares$7.9 Million0.01% of portfolio
-
Ubs Group Ag249KShares$1.44 Million0.0% of portfolio
-
Morgan Stanley New York, NY220KShares$1.28 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il60.5KShares$350,1560.0% of portfolio
-
Jane Street Group, LLC New York, NY46.1KShares$266,9760.0% of portfolio
About KAZIA THERAPEUTICS LTD
- Ticker KZIA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,111,300
- Market Cap $87.5M
- Description
- Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...